{"transactions":[{"id":4635422,"issuer":{"id":606,"kind":"organization","name":"Revolution Medicines, Inc.","symbol":"RVMD"},"owners":[{"id":55791,"kind":"person","name":"Sandler Alan B.","position":1,"cik":"0001835966","reported_name":"Sandler Alan B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-10-02T02:00:04.000Z","date":"2026-09-29","kind":"exercise","planned":true,"acquired":false,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on June 30, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"Twenty-five percent of the total shares subject to the option will vest on the first year anniversary measured from September 29, 2025 (the \"Vesting Commencement Date\") and one forty-eighth (1/48th) of the shares subject to the option will vest on each monthly anniversary of the Vesting Commencement Date thereafter, so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date."}],"balance_after":161300,"derivative":{"exercise_price":58.84,"expiration_date":"2035-11-01","underlying":"Common Stock","underlying_shares":167300},"source":{"system":"sec-edgar","filing":"0001835966-26-000008","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1628171/000183596626000008/ownership.xml","form_type":"4"}},{"id":4635421,"issuer":{"id":606,"kind":"organization","name":"Revolution Medicines, Inc.","symbol":"RVMD"},"owners":[{"id":55791,"kind":"person","name":"Sandler Alan B.","position":1,"cik":"0001835966","reported_name":"Sandler Alan B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2026-10-02T02:00:04.000Z","date":"2026-09-29","kind":"sale","planned":true,"acquired":false,"shares":301,"price":204.7224,"value":61621.4424,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on June 30, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The transaction was executed in multiple trades at prices ranging from $204.43 to $204.83, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F7","text":"Includes 52,350 restricted stock units."}],"balance_after":52559,"source":{"system":"sec-edgar","filing":"0001835966-26-000008","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1628171/000183596626000008/ownership.xml","form_type":"4"}},{"id":4635420,"issuer":{"id":606,"kind":"organization","name":"Revolution Medicines, Inc.","symbol":"RVMD"},"owners":[{"id":55791,"kind":"person","name":"Sandler Alan B.","position":1,"cik":"0001835966","reported_name":"Sandler Alan B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2026-10-02T02:00:04.000Z","date":"2026-09-29","kind":"sale","planned":true,"acquired":false,"shares":1199,"price":203.9074,"value":244484.9726,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on June 30, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The transaction was executed in multiple trades at prices ranging from $203.42 to $204.29, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."}],"balance_after":52860,"source":{"system":"sec-edgar","filing":"0001835966-26-000008","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1628171/000183596626000008/ownership.xml","form_type":"4"}},{"id":4635419,"issuer":{"id":606,"kind":"organization","name":"Revolution Medicines, Inc.","symbol":"RVMD"},"owners":[{"id":55791,"kind":"person","name":"Sandler Alan B.","position":1,"cik":"0001835966","reported_name":"Sandler Alan B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2026-10-02T02:00:04.000Z","date":"2026-09-29","kind":"sale","planned":true,"acquired":false,"shares":1000,"price":202.8127,"value":202812.7,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on June 30, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transaction was executed in multiple trades at prices ranging from $202.42 to $203.34, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."}],"balance_after":54059,"source":{"system":"sec-edgar","filing":"0001835966-26-000008","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1628171/000183596626000008/ownership.xml","form_type":"4"}},{"id":4635418,"issuer":{"id":606,"kind":"organization","name":"Revolution Medicines, Inc.","symbol":"RVMD"},"owners":[{"id":55791,"kind":"person","name":"Sandler Alan B.","position":1,"cik":"0001835966","reported_name":"Sandler Alan B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2026-10-02T02:00:04.000Z","date":"2026-09-29","kind":"sale","planned":true,"acquired":false,"shares":1609,"price":201.7239,"value":324573.7551,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on June 30, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transaction was executed in multiple trades at prices ranging from $201.41 to $202.16, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."}],"balance_after":55059,"source":{"system":"sec-edgar","filing":"0001835966-26-000008","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1628171/000183596626000008/ownership.xml","form_type":"4"}},{"id":4635417,"issuer":{"id":606,"kind":"organization","name":"Revolution Medicines, Inc.","symbol":"RVMD"},"owners":[{"id":55791,"kind":"person","name":"Sandler Alan B.","position":1,"cik":"0001835966","reported_name":"Sandler Alan B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2026-10-02T02:00:04.000Z","date":"2026-09-29","kind":"sale","planned":true,"acquired":false,"shares":2200,"price":200.8188,"value":441801.36,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on June 30, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transaction was executed in multiple trades at prices ranging from $200.41 to $201.38, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."}],"balance_after":56668,"source":{"system":"sec-edgar","filing":"0001835966-26-000008","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1628171/000183596626000008/ownership.xml","form_type":"4"}},{"id":4635416,"issuer":{"id":606,"kind":"organization","name":"Revolution Medicines, Inc.","symbol":"RVMD"},"owners":[{"id":55791,"kind":"person","name":"Sandler Alan B.","position":1,"cik":"0001835966","reported_name":"Sandler Alan B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2026-10-02T02:00:04.000Z","date":"2026-09-29","kind":"exercise","planned":true,"acquired":true,"shares":6000,"price":58.84,"value":353040.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on June 30, 2026."}],"balance_after":58868,"source":{"system":"sec-edgar","filing":"0001835966-26-000008","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1628171/000183596626000008/ownership.xml","form_type":"4"}},{"id":4635423,"issuer":{"id":606,"kind":"organization","name":"Revolution Medicines, Inc.","symbol":"RVMD"},"owners":[{"id":19800,"kind":"person","name":"Cislini Jeff","position":1,"cik":"0001969082","reported_name":"Cislini Jeff","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & General Counsel"}}],"security":"Common Stock","published_at":"2026-09-30T02:00:09.000Z","date":"2026-09-25","kind":"sale","planned":true,"acquired":false,"shares":765,"price":207.3201,"value":158599.8765,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on May 22, 2026."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 37,088 restricted stock units."}],"balance_after":51776,"source":{"system":"sec-edgar","filing":"0001969082-26-000011","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1628171/000196908226000011/ownership.xml","form_type":"4"}},{"id":4627840,"issuer":{"id":606,"kind":"organization","name":"Revolution Medicines, Inc.","symbol":"RVMD"},"owners":[{"id":36687,"kind":"person","name":"Mancini Anthony","position":1,"cik":"0002124509","reported_name":"Mancini Anthony","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-28T22:00:04.000Z","date":"2026-09-25","kind":"exercise","planned":true,"acquired":false,"shares":3121,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by Anthony Mancini on June 11, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Twenty-five percent of the total shares subject to the option will vest on the first year anniversary measured from April 1, 2025 (the \"Vesting Commencement Date\") and one forty-eighth (1/48th) of the shares subject to the option will vest on each monthly anniversary of the Vesting Commencement Date thereafter, so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date."}],"balance_after":93625,"derivative":{"exercise_price":33.62,"expiration_date":"2035-03-31","underlying":"Common Stock","underlying_shares":3121},"source":{"system":"sec-edgar","filing":"0002124509-26-000012","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2124509/000212450926000012/ownership.xml","form_type":"4"}},{"id":4627839,"issuer":{"id":606,"kind":"organization","name":"Revolution Medicines, Inc.","symbol":"RVMD"},"owners":[{"id":36687,"kind":"person","name":"Mancini Anthony","position":1,"cik":"0002124509","reported_name":"Mancini Anthony","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-09-28T22:00:04.000Z","date":"2026-09-25","kind":"sale","planned":true,"acquired":false,"shares":3121,"price":200.54,"value":625885.34,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by Anthony Mancini on June 11, 2026."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 39,575 restricted stock units."}],"balance_after":39765,"source":{"system":"sec-edgar","filing":"0002124509-26-000012","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2124509/000212450926000012/ownership.xml","form_type":"4"}},{"id":4627838,"issuer":{"id":606,"kind":"organization","name":"Revolution Medicines, Inc.","symbol":"RVMD"},"owners":[{"id":36687,"kind":"person","name":"Mancini Anthony","position":1,"cik":"0002124509","reported_name":"Mancini Anthony","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-09-28T22:00:04.000Z","date":"2026-09-25","kind":"exercise","planned":true,"acquired":true,"shares":3121,"price":33.62,"value":104928.02,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by Anthony Mancini on June 11, 2026."}],"balance_after":42886,"source":{"system":"sec-edgar","filing":"0002124509-26-000012","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2124509/000212450926000012/ownership.xml","form_type":"4"}},{"id":4627837,"issuer":{"id":606,"kind":"organization","name":"Revolution Medicines, Inc.","symbol":"RVMD"},"owners":[{"id":36687,"kind":"person","name":"Mancini Anthony","position":1,"cik":"0002124509","reported_name":"Mancini Anthony","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-09-28T22:00:04.000Z","date":"2026-09-24","kind":"sale","planned":true,"acquired":false,"shares":587,"price":200,"value":117400.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by Anthony Mancini on June 11, 2026."}],"balance_after":39765,"source":{"system":"sec-edgar","filing":"0002124509-26-000012","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2124509/000212450926000012/ownership.xml","form_type":"4"}},{"id":4626398,"issuer":{"id":606,"kind":"organization","name":"Revolution Medicines, Inc.","symbol":"RVMD"},"owners":[{"id":35893,"kind":"person","name":"ANDERSON ELIZABETH M","position":1,"cik":"0001758247","reported_name":"ANDERSON ELIZABETH M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-24T22:00:04.000Z","date":"2026-09-22","kind":"exercise","planned":true,"acquired":false,"shares":5070,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on June 23, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"Fully vested."}],"balance_after":1095,"derivative":{"exercise_price":1.12,"expiration_date":"2028-04-19","underlying":"Common Stock","underlying_shares":6165},"source":{"system":"sec-edgar","filing":"0001758247-26-000004","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1758247/000175824726000004/ownership.xml","form_type":"4"}},{"id":4626397,"issuer":{"id":606,"kind":"organization","name":"Revolution Medicines, Inc.","symbol":"RVMD"},"owners":[{"id":35893,"kind":"person","name":"ANDERSON ELIZABETH M","position":1,"cik":"0001758247","reported_name":"ANDERSON ELIZABETH M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-09-24T22:00:04.000Z","date":"2026-09-22","kind":"sale","planned":true,"acquired":false,"shares":100,"price":195.15,"value":19515.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on June 23, 2026."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F6","text":"Includes 1,191 restricted stock units."}],"balance_after":4333,"source":{"system":"sec-edgar","filing":"0001758247-26-000004","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1758247/000175824726000004/ownership.xml","form_type":"4"}},{"id":4626396,"issuer":{"id":606,"kind":"organization","name":"Revolution Medicines, Inc.","symbol":"RVMD"},"owners":[{"id":35893,"kind":"person","name":"ANDERSON ELIZABETH M","position":1,"cik":"0001758247","reported_name":"ANDERSON ELIZABETH M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-09-24T22:00:04.000Z","date":"2026-09-22","kind":"sale","planned":true,"acquired":false,"shares":1500,"price":194.5887,"value":291883.05,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on June 23, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The transaction was executed in multiple trades at prices ranging from $194.04 to $194.96, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."}],"balance_after":4433,"source":{"system":"sec-edgar","filing":"0001758247-26-000004","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1758247/000175824726000004/ownership.xml","form_type":"4"}},{"id":4626395,"issuer":{"id":606,"kind":"organization","name":"Revolution Medicines, Inc.","symbol":"RVMD"},"owners":[{"id":35893,"kind":"person","name":"ANDERSON ELIZABETH M","position":1,"cik":"0001758247","reported_name":"ANDERSON ELIZABETH M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-09-24T22:00:04.000Z","date":"2026-09-22","kind":"sale","planned":true,"acquired":false,"shares":2648,"price":193.4392,"value":512227.0016,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on June 23, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transaction was executed in multiple trades at prices ranging from $193.00 to $193.81, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."}],"balance_after":5933,"source":{"system":"sec-edgar","filing":"0001758247-26-000004","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1758247/000175824726000004/ownership.xml","form_type":"4"}},{"id":4626394,"issuer":{"id":606,"kind":"organization","name":"Revolution Medicines, Inc.","symbol":"RVMD"},"owners":[{"id":35893,"kind":"person","name":"ANDERSON ELIZABETH M","position":1,"cik":"0001758247","reported_name":"ANDERSON ELIZABETH M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-09-24T22:00:04.000Z","date":"2026-09-22","kind":"sale","planned":true,"acquired":false,"shares":4985,"price":192.5387,"value":959805.4195,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on June 23, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transaction was executed in multiple trades at prices ranging from $192.01 to $192.99, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."}],"balance_after":8581,"source":{"system":"sec-edgar","filing":"0001758247-26-000004","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1758247/000175824726000004/ownership.xml","form_type":"4"}},{"id":4626393,"issuer":{"id":606,"kind":"organization","name":"Revolution Medicines, Inc.","symbol":"RVMD"},"owners":[{"id":35893,"kind":"person","name":"ANDERSON ELIZABETH M","position":1,"cik":"0001758247","reported_name":"ANDERSON ELIZABETH M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-09-24T22:00:04.000Z","date":"2026-09-22","kind":"sale","planned":true,"acquired":false,"shares":910,"price":191.8521,"value":174585.411,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on June 23, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transaction was executed in multiple trades at prices ranging from $191.65 to $191.99, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."}],"balance_after":13566,"source":{"system":"sec-edgar","filing":"0001758247-26-000004","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1758247/000175824726000004/ownership.xml","form_type":"4"}},{"id":4626392,"issuer":{"id":606,"kind":"organization","name":"Revolution Medicines, Inc.","symbol":"RVMD"},"owners":[{"id":35893,"kind":"person","name":"ANDERSON ELIZABETH M","position":1,"cik":"0001758247","reported_name":"ANDERSON ELIZABETH M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-09-24T22:00:04.000Z","date":"2026-09-22","kind":"exercise","planned":true,"acquired":true,"shares":5070,"price":1.12,"value":5678.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on June 23, 2026."}],"balance_after":14476,"source":{"system":"sec-edgar","filing":"0001758247-26-000004","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1758247/000175824726000004/ownership.xml","form_type":"4"}},{"id":4624917,"issuer":{"id":606,"kind":"organization","name":"Revolution Medicines, Inc.","symbol":"RVMD"},"owners":[{"id":36687,"kind":"person","name":"Mancini Anthony","position":1,"cik":"0002124509","reported_name":"Mancini Anthony","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-09-22T22:00:03.000Z","date":"2026-09-18","kind":"sale","planned":true,"acquired":false,"shares":1764,"price":196.94,"value":347402.16,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by Anthony Mancini on June 11, 2026."}],"balance_after":40352,"source":{"system":"sec-edgar","filing":"0002124509-26-000010","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2124509/000212450926000010/ownership.xml","form_type":"4"}},{"id":4624334,"issuer":{"id":606,"kind":"organization","name":"Revolution Medicines, Inc.","symbol":"RVMD"},"owners":[{"id":55791,"kind":"person","name":"Sandler Alan B.","position":1,"cik":"0001835966","reported_name":"Sandler Alan B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2026-09-18T22:06:03.000Z","date":"2026-09-16","kind":"sale","planned":true,"acquired":false,"shares":336,"price":199.3032,"value":66965.8752,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on June 13, 2026 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 52,350 restricted stock units."}],"balance_after":52868,"source":{"system":"sec-edgar","filing":"0001835966-26-000006","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1628171/000183596626000006/ownership.xml","form_type":"4"}},{"id":4624333,"issuer":{"id":606,"kind":"organization","name":"Revolution Medicines, Inc.","symbol":"RVMD"},"owners":[{"id":55791,"kind":"person","name":"Sandler Alan B.","position":1,"cik":"0001835966","reported_name":"Sandler Alan B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2026-09-18T22:06:03.000Z","date":"2026-09-16","kind":"sale","planned":true,"acquired":false,"shares":5,"price":194.9589,"value":974.7945,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on June 13, 2026 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 209 shares acquired under the Issuer's Employee Stock Purchase Plan on May 31, 2026."}],"balance_after":53204,"source":{"system":"sec-edgar","filing":"0001835966-26-000006","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1628171/000183596626000006/ownership.xml","form_type":"4"}},{"id":4624336,"issuer":{"id":606,"kind":"organization","name":"Revolution Medicines, Inc.","symbol":"RVMD"},"owners":[{"id":36687,"kind":"person","name":"Mancini Anthony","position":1,"cik":"0002124509","reported_name":"Mancini Anthony","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-09-18T22:05:04.000Z","date":"2026-09-16","kind":"sale","planned":true,"acquired":false,"shares":1747,"price":199.3032,"value":348182.6904,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on June 15, 2026 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 39,575 restricted stock units."}],"balance_after":42116,"source":{"system":"sec-edgar","filing":"0002124509-26-000008","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1628171/000212450926000008/ownership.xml","form_type":"4"}},{"id":4624335,"issuer":{"id":606,"kind":"organization","name":"Revolution Medicines, Inc.","symbol":"RVMD"},"owners":[{"id":36687,"kind":"person","name":"Mancini Anthony","position":1,"cik":"0002124509","reported_name":"Mancini Anthony","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-09-18T22:05:04.000Z","date":"2026-09-16","kind":"sale","planned":true,"acquired":false,"shares":27,"price":195.0521,"value":5266.4067,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on June 15, 2026 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transaction was executed in multiple trades at prices ranging from $195.03 to $195.07, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."}],"balance_after":43863,"source":{"system":"sec-edgar","filing":"0002124509-26-000008","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1628171/000212450926000008/ownership.xml","form_type":"4"}},{"id":4624161,"issuer":{"id":606,"kind":"organization","name":"Revolution Medicines, Inc.","symbol":"RVMD"},"owners":[{"id":36791,"kind":"person","name":"Kelsey Stephen Michael","position":1,"cik":"0001462808","reported_name":"Kelsey Stephen Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-09-18T22:04:03.000Z","date":"2026-09-16","kind":"sale","planned":true,"acquired":false,"shares":5484,"price":199.3032,"value":1092978.7488,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 65,613 restricted stock units."}],"balance_after":286307,"source":{"system":"sec-edgar","filing":"0001462808-26-000010","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1462808/000146280826000010/ownership.xml","form_type":"4"}},{"id":4624160,"issuer":{"id":606,"kind":"organization","name":"Revolution Medicines, Inc.","symbol":"RVMD"},"owners":[{"id":36791,"kind":"person","name":"Kelsey Stephen Michael","position":1,"cik":"0001462808","reported_name":"Kelsey Stephen Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-09-18T22:04:03.000Z","date":"2026-09-16","kind":"sale","planned":true,"acquired":false,"shares":85,"price":195.0074,"value":16575.629,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transaction was executed in multiple trades at prices ranging from $195.00 to $195.03, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."}],"balance_after":291791,"source":{"system":"sec-edgar","filing":"0001462808-26-000010","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1462808/000146280826000010/ownership.xml","form_type":"4"}},{"id":4624226,"issuer":{"id":606,"kind":"organization","name":"Revolution Medicines, Inc.","symbol":"RVMD"},"owners":[{"id":37201,"kind":"person","name":"Horn Margaret A","position":1,"cik":"0001294192","reported_name":"Horn Margaret A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2026-09-18T22:03:05.000Z","date":"2026-09-16","kind":"sale","planned":true,"acquired":false,"shares":4891,"price":199.3032,"value":974791.9512,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 56,713 restricted stock units."}],"balance_after":149680,"source":{"system":"sec-edgar","filing":"0001294192-26-000007","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1294192/000129419226000007/ownership.xml","form_type":"4"}},{"id":4624225,"issuer":{"id":606,"kind":"organization","name":"Revolution Medicines, Inc.","symbol":"RVMD"},"owners":[{"id":37201,"kind":"person","name":"Horn Margaret A","position":1,"cik":"0001294192","reported_name":"Horn Margaret A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2026-09-18T22:03:05.000Z","date":"2026-09-16","kind":"sale","planned":true,"acquired":false,"shares":76,"price":195.0083,"value":14820.6308,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transaction was executed in multiple trades at prices ranging from $195.00 to $195.03, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."}],"balance_after":154571,"source":{"system":"sec-edgar","filing":"0001294192-26-000007","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1294192/000129419226000007/ownership.xml","form_type":"4"}},{"id":4624228,"issuer":{"id":606,"kind":"organization","name":"Revolution Medicines, Inc.","symbol":"RVMD"},"owners":[{"id":19850,"kind":"person","name":"GOLDSMITH MARK A","position":1,"cik":"0001246842","reported_name":"GOLDSMITH MARK A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-09-18T22:02:05.000Z","date":"2026-09-16","kind":"sale","planned":true,"acquired":false,"shares":13775,"price":199.3032,"value":2745401.58,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 157,588 restricted stock units."}],"balance_after":253342,"source":{"system":"sec-edgar","filing":"0001246842-26-000008","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1246842/000124684226000008/ownership.xml","form_type":"4"}},{"id":4624227,"issuer":{"id":606,"kind":"organization","name":"Revolution Medicines, Inc.","symbol":"RVMD"},"owners":[{"id":19850,"kind":"person","name":"GOLDSMITH MARK A","position":1,"cik":"0001246842","reported_name":"GOLDSMITH MARK A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-09-18T22:02:05.000Z","date":"2026-09-16","kind":"sale","planned":true,"acquired":false,"shares":213,"price":195.0085,"value":41536.8105,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transaction was executed in multiple trades at prices ranging from $195.00 to $195.03, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."}],"balance_after":267117,"source":{"system":"sec-edgar","filing":"0001246842-26-000008","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1246842/000124684226000008/ownership.xml","form_type":"4"}},{"id":4624338,"issuer":{"id":606,"kind":"organization","name":"Revolution Medicines, Inc.","symbol":"RVMD"},"owners":[{"id":19800,"kind":"person","name":"Cislini Jeff","position":1,"cik":"0001969082","reported_name":"Cislini Jeff","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & General Counsel"}}],"security":"Common Stock","published_at":"2026-09-18T22:01:03.000Z","date":"2026-09-16","kind":"sale","planned":true,"acquired":false,"shares":3314,"price":199.3032,"value":660490.8048,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 37,088 restricted stock units."}],"balance_after":52541,"source":{"system":"sec-edgar","filing":"0001969082-26-000009","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1628171/000196908226000009/ownership.xml","form_type":"4"}},{"id":4624337,"issuer":{"id":606,"kind":"organization","name":"Revolution Medicines, Inc.","symbol":"RVMD"},"owners":[{"id":19800,"kind":"person","name":"Cislini Jeff","position":1,"cik":"0001969082","reported_name":"Cislini Jeff","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & General Counsel"}}],"security":"Common Stock","published_at":"2026-09-18T22:01:03.000Z","date":"2026-09-16","kind":"sale","planned":true,"acquired":false,"shares":52,"price":195.0087,"value":10140.4524,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transaction was executed in multiple trades at prices ranging from $195.00 to $195.03, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."}],"balance_after":55855,"source":{"system":"sec-edgar","filing":"0001969082-26-000009","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1628171/000196908226000009/ownership.xml","form_type":"4"}},{"id":4624138,"issuer":{"id":606,"kind":"organization","name":"Revolution Medicines, Inc.","symbol":"RVMD"},"owners":[{"id":35163,"kind":"person","name":"Anders Jack","position":1,"cik":"0001800668","reported_name":"Anders Jack","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-09-18T22:00:03.000Z","date":"2026-09-16","kind":"sale","planned":true,"acquired":false,"shares":3992,"price":199.3032,"value":795618.3744,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 43,650 restricted stock units."}],"balance_after":119216,"source":{"system":"sec-edgar","filing":"0001800668-26-000007","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1800668/000180066826000007/ownership.xml","form_type":"4"}},{"id":4624137,"issuer":{"id":606,"kind":"organization","name":"Revolution Medicines, Inc.","symbol":"RVMD"},"owners":[{"id":35163,"kind":"person","name":"Anders Jack","position":1,"cik":"0001800668","reported_name":"Anders Jack","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-09-18T22:00:03.000Z","date":"2026-09-16","kind":"sale","planned":true,"acquired":false,"shares":61,"price":195,"value":11895.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units."}],"balance_after":123208,"source":{"system":"sec-edgar","filing":"0001800668-26-000007","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1800668/000180066826000007/ownership.xml","form_type":"4"}},{"id":4618554,"issuer":{"id":606,"kind":"organization","name":"Revolution Medicines, Inc.","symbol":"RVMD"},"owners":[{"id":36791,"kind":"person","name":"Kelsey Stephen Michael","position":1,"cik":"0001462808","reported_name":"Kelsey Stephen Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-15T22:00:04.000Z","date":"2026-09-11","kind":"exercise","planned":true,"acquired":false,"shares":40031,"price":40.74,"value":1630862.94,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by Stephen Kelsey on June 12, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F12","text":"One forty-eighth (1/48th) of the shares initially subject to the option will vest on each monthly anniversary measured from March 1, 2025 (the \"Vesting Commencement Date\"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date."}],"balance_after":88069,"derivative":{"exercise_price":40.74,"expiration_date":"2035-03-01","underlying":"Common Stock","underlying_shares":128100},"source":{"system":"sec-edgar","filing":"0001462808-26-000007","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1628171/000146280826000007/ownership.xml","form_type":"4"}},{"id":4618553,"issuer":{"id":606,"kind":"organization","name":"Revolution Medicines, Inc.","symbol":"RVMD"},"owners":[{"id":36791,"kind":"person","name":"Kelsey Stephen Michael","position":1,"cik":"0001462808","reported_name":"Kelsey Stephen Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-15T22:00:04.000Z","date":"2026-09-11","kind":"exercise","planned":true,"acquired":false,"shares":52500,"price":42.45,"value":2228625.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by Stephen Kelsey on June 12, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"Fully vested."}],"balance_after":0,"derivative":{"exercise_price":42.45,"expiration_date":"2031-03-04","underlying":"Common Stock","underlying_shares":52500},"source":{"system":"sec-edgar","filing":"0001462808-26-000007","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1628171/000146280826000007/ownership.xml","form_type":"4"}},{"id":4618552,"issuer":{"id":606,"kind":"organization","name":"Revolution Medicines, Inc.","symbol":"RVMD"},"owners":[{"id":36791,"kind":"person","name":"Kelsey Stephen Michael","position":1,"cik":"0001462808","reported_name":"Kelsey Stephen Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-09-15T22:00:04.000Z","date":"2026-09-11","kind":"sale","planned":true,"acquired":false,"shares":3270,"price":205.8075,"value":672990.525,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by Stephen Kelsey on June 12, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The transaction was executed in multiple trades at prices ranging from $205.57 to $206.05, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F10","text":"Includes 76,251 restricted stock units."}],"balance_after":291876,"source":{"system":"sec-edgar","filing":"0001462808-26-000007","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1628171/000146280826000007/ownership.xml","form_type":"4"}},{"id":4618551,"issuer":{"id":606,"kind":"organization","name":"Revolution Medicines, Inc.","symbol":"RVMD"},"owners":[{"id":36791,"kind":"person","name":"Kelsey Stephen Michael","position":1,"cik":"0001462808","reported_name":"Kelsey Stephen Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-09-15T22:00:04.000Z","date":"2026-09-11","kind":"sale","planned":true,"acquired":false,"shares":4995,"price":204.8427,"value":1023189.2865,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by Stephen Kelsey on June 12, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The transaction was executed in multiple trades at prices ranging from $204.46 to $205.45, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."}],"balance_after":295146,"source":{"system":"sec-edgar","filing":"0001462808-26-000007","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1628171/000146280826000007/ownership.xml","form_type":"4"}},{"id":4618550,"issuer":{"id":606,"kind":"organization","name":"Revolution Medicines, Inc.","symbol":"RVMD"},"owners":[{"id":36791,"kind":"person","name":"Kelsey Stephen Michael","position":1,"cik":"0001462808","reported_name":"Kelsey Stephen Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-09-15T22:00:04.000Z","date":"2026-09-11","kind":"sale","planned":true,"acquired":false,"shares":17949,"price":203.8726,"value":3659309.2974,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by Stephen Kelsey on June 12, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The transaction was executed in multiple trades at prices ranging from $203.45 to $204.42, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."}],"balance_after":300141,"source":{"system":"sec-edgar","filing":"0001462808-26-000007","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1628171/000146280826000007/ownership.xml","form_type":"4"}},{"id":4618549,"issuer":{"id":606,"kind":"organization","name":"Revolution Medicines, Inc.","symbol":"RVMD"},"owners":[{"id":36791,"kind":"person","name":"Kelsey Stephen Michael","position":1,"cik":"0001462808","reported_name":"Kelsey Stephen Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-09-15T22:00:04.000Z","date":"2026-09-11","kind":"sale","planned":true,"acquired":false,"shares":18869,"price":203.0606,"value":3831550.4614,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by Stephen Kelsey on June 12, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The transaction was executed in multiple trades at prices ranging from $202.41 to $203.40, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."}],"balance_after":318090,"source":{"system":"sec-edgar","filing":"0001462808-26-000007","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1628171/000146280826000007/ownership.xml","form_type":"4"}},{"id":4618548,"issuer":{"id":606,"kind":"organization","name":"Revolution Medicines, Inc.","symbol":"RVMD"},"owners":[{"id":36791,"kind":"person","name":"Kelsey Stephen Michael","position":1,"cik":"0001462808","reported_name":"Kelsey Stephen Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-09-15T22:00:04.000Z","date":"2026-09-11","kind":"sale","planned":true,"acquired":false,"shares":21447,"price":201.7507,"value":4326947.2629,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by Stephen Kelsey on June 12, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The transaction was executed in multiple trades at prices ranging from $201.39 to $202.37, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."}],"balance_after":336959,"source":{"system":"sec-edgar","filing":"0001462808-26-000007","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1628171/000146280826000007/ownership.xml","form_type":"4"}},{"id":4618547,"issuer":{"id":606,"kind":"organization","name":"Revolution Medicines, Inc.","symbol":"RVMD"},"owners":[{"id":36791,"kind":"person","name":"Kelsey Stephen Michael","position":1,"cik":"0001462808","reported_name":"Kelsey Stephen Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-09-15T22:00:04.000Z","date":"2026-09-11","kind":"sale","planned":true,"acquired":false,"shares":13368,"price":200.7769,"value":2683985.5992,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by Stephen Kelsey on June 12, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transaction was executed in multiple trades at prices ranging from $200.36 to $201.33, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."}],"balance_after":358406,"source":{"system":"sec-edgar","filing":"0001462808-26-000007","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1628171/000146280826000007/ownership.xml","form_type":"4"}},{"id":4618546,"issuer":{"id":606,"kind":"organization","name":"Revolution Medicines, Inc.","symbol":"RVMD"},"owners":[{"id":36791,"kind":"person","name":"Kelsey Stephen Michael","position":1,"cik":"0001462808","reported_name":"Kelsey Stephen Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-09-15T22:00:04.000Z","date":"2026-09-11","kind":"sale","planned":true,"acquired":false,"shares":11833,"price":200.1145,"value":2367954.8785,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by Stephen Kelsey on June 12, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transaction was executed in multiple trades at prices ranging from $199.36 to $200.35, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."}],"balance_after":371774,"source":{"system":"sec-edgar","filing":"0001462808-26-000007","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1628171/000146280826000007/ownership.xml","form_type":"4"}},{"id":4618545,"issuer":{"id":606,"kind":"organization","name":"Revolution Medicines, Inc.","symbol":"RVMD"},"owners":[{"id":36791,"kind":"person","name":"Kelsey Stephen Michael","position":1,"cik":"0001462808","reported_name":"Kelsey Stephen Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-09-15T22:00:04.000Z","date":"2026-09-11","kind":"sale","planned":true,"acquired":false,"shares":800,"price":198.5502,"value":158840.16,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by Stephen Kelsey on June 12, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transaction was executed in multiple trades at prices ranging from $198.35 to $198.96, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."}],"balance_after":383607,"source":{"system":"sec-edgar","filing":"0001462808-26-000007","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1628171/000146280826000007/ownership.xml","form_type":"4"}},{"id":4618544,"issuer":{"id":606,"kind":"organization","name":"Revolution Medicines, Inc.","symbol":"RVMD"},"owners":[{"id":36791,"kind":"person","name":"Kelsey Stephen Michael","position":1,"cik":"0001462808","reported_name":"Kelsey Stephen Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-09-15T22:00:04.000Z","date":"2026-09-11","kind":"exercise","planned":true,"acquired":true,"shares":40031,"price":40.74,"value":1630862.94,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by Stephen Kelsey on June 12, 2026."}],"balance_after":384407,"source":{"system":"sec-edgar","filing":"0001462808-26-000007","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1628171/000146280826000007/ownership.xml","form_type":"4"}},{"id":4618543,"issuer":{"id":606,"kind":"organization","name":"Revolution Medicines, Inc.","symbol":"RVMD"},"owners":[{"id":36791,"kind":"person","name":"Kelsey Stephen Michael","position":1,"cik":"0001462808","reported_name":"Kelsey Stephen Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-09-15T22:00:04.000Z","date":"2026-09-11","kind":"exercise","planned":true,"acquired":true,"shares":52500,"price":42.45,"value":2228625.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by Stephen Kelsey on June 12, 2026."}],"balance_after":344376,"source":{"system":"sec-edgar","filing":"0001462808-26-000007","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1628171/000146280826000007/ownership.xml","form_type":"4"}},{"id":4617427,"issuer":{"id":606,"kind":"organization","name":"Revolution Medicines, Inc.","symbol":"RVMD"},"owners":[{"id":36687,"kind":"person","name":"Mancini Anthony","position":1,"cik":"0002124509","reported_name":"Mancini Anthony","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-14T22:03:59.000Z","date":"2026-09-10","kind":"exercise","planned":true,"acquired":false,"shares":9363,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by Anthony Mancini on June 11, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"Twenty-five percent of the total shares subject to the option will vest on the first year anniversary measured from April 1, 2025 (the \"Vesting Commencement Date\") and one forty-eighth (1/48th) of the shares subject to the option will vest on each monthly anniversary of the Vesting Commencement Date thereafter, so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date."}],"balance_after":96746,"derivative":{"exercise_price":33.62,"expiration_date":"2035-03-31","underlying":"Common Stock","underlying_shares":9363},"source":{"system":"sec-edgar","filing":"0002124509-26-000004","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/2124509/000212450926000004/ownership.xml","form_type":"4"}},{"id":4617426,"issuer":{"id":606,"kind":"organization","name":"Revolution Medicines, Inc.","symbol":"RVMD"},"owners":[{"id":36687,"kind":"person","name":"Mancini Anthony","position":1,"cik":"0002124509","reported_name":"Mancini Anthony","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-09-14T22:03:59.000Z","date":"2026-09-10","kind":"sale","planned":true,"acquired":false,"shares":300,"price":207.1733,"value":62151.99,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by Anthony Mancini on June 11, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The transaction was executed in multiple trades at prices ranging from $207.12 to $207.28, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F7","text":"Includes 43,700 restricted stock units."}],"balance_after":43890,"source":{"system":"sec-edgar","filing":"0002124509-26-000004","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/2124509/000212450926000004/ownership.xml","form_type":"4"}},{"id":4617425,"issuer":{"id":606,"kind":"organization","name":"Revolution Medicines, Inc.","symbol":"RVMD"},"owners":[{"id":36687,"kind":"person","name":"Mancini Anthony","position":1,"cik":"0002124509","reported_name":"Mancini Anthony","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-09-14T22:03:59.000Z","date":"2026-09-10","kind":"sale","planned":true,"acquired":false,"shares":1179,"price":206.0995,"value":242991.3105,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by Anthony Mancini on June 11, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The transaction was executed in multiple trades at prices ranging from $205.85 to $206.70, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."}],"balance_after":44190,"source":{"system":"sec-edgar","filing":"0002124509-26-000004","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/2124509/000212450926000004/ownership.xml","form_type":"4"}},{"id":4617424,"issuer":{"id":606,"kind":"organization","name":"Revolution Medicines, Inc.","symbol":"RVMD"},"owners":[{"id":36687,"kind":"person","name":"Mancini Anthony","position":1,"cik":"0002124509","reported_name":"Mancini Anthony","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-09-14T22:03:59.000Z","date":"2026-09-10","kind":"sale","planned":true,"acquired":false,"shares":2420,"price":205.0513,"value":496224.146,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by Anthony Mancini on June 11, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transaction was executed in multiple trades at prices ranging from $204.64 to $205.55, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."}],"balance_after":45369,"source":{"system":"sec-edgar","filing":"0002124509-26-000004","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2124509/000212450926000004/ownership.xml","form_type":"4"}},{"id":4617423,"issuer":{"id":606,"kind":"organization","name":"Revolution Medicines, Inc.","symbol":"RVMD"},"owners":[{"id":36687,"kind":"person","name":"Mancini Anthony","position":1,"cik":"0002124509","reported_name":"Mancini Anthony","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-09-14T22:03:59.000Z","date":"2026-09-10","kind":"sale","planned":true,"acquired":false,"shares":5530,"price":204.1357,"value":1128870.421,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by Anthony Mancini on June 11, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transaction was executed in multiple trades at prices ranging from $203.64 to $204.63, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."}],"balance_after":47789,"source":{"system":"sec-edgar","filing":"0002124509-26-000004","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2124509/000212450926000004/ownership.xml","form_type":"4"}},{"id":4617422,"issuer":{"id":606,"kind":"organization","name":"Revolution Medicines, Inc.","symbol":"RVMD"},"owners":[{"id":36687,"kind":"person","name":"Mancini Anthony","position":1,"cik":"0002124509","reported_name":"Mancini Anthony","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-09-14T22:03:59.000Z","date":"2026-09-10","kind":"sale","planned":true,"acquired":false,"shares":6019,"price":203.2844,"value":1223568.8036,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by Anthony Mancini on June 11, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transaction was executed in multiple trades at prices ranging from $202.64 to $203.63, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."}],"balance_after":53319,"source":{"system":"sec-edgar","filing":"0002124509-26-000004","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2124509/000212450926000004/ownership.xml","form_type":"4"}},{"id":4617421,"issuer":{"id":606,"kind":"organization","name":"Revolution Medicines, Inc.","symbol":"RVMD"},"owners":[{"id":36687,"kind":"person","name":"Mancini Anthony","position":1,"cik":"0002124509","reported_name":"Mancini Anthony","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-09-14T22:03:59.000Z","date":"2026-09-10","kind":"exercise","planned":true,"acquired":true,"shares":9363,"price":33.62,"value":314784.06,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by Anthony Mancini on June 11, 2026."}],"balance_after":59338,"source":{"system":"sec-edgar","filing":"0002124509-26-000004","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2124509/000212450926000004/ownership.xml","form_type":"4"}},{"id":4615081,"issuer":{"id":606,"kind":"organization","name":"Revolution Medicines, Inc.","symbol":"RVMD"},"owners":[{"id":607,"kind":"person","name":"Kim Lorence H.","position":1,"cik":"0001643746","reported_name":"Kim Lorence H.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-09-10T21:52:37.000Z","date":"2026-09-08","kind":"sale","planned":true,"acquired":false,"shares":371,"price":212.2693,"value":78751.9103,"ownership":{"direct":false,"nature":"Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Lorence Kim Revocable Trust on June 1, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The transaction was executed in multiple trades at prices ranging from $212.0775 to $212.3903, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Shares held by the Lorence Kim Revocable Trust."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001193125-26-388156","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1643746/000119312526388156/ownership.xml","form_type":"4"}},{"id":4615080,"issuer":{"id":606,"kind":"organization","name":"Revolution Medicines, Inc.","symbol":"RVMD"},"owners":[{"id":607,"kind":"person","name":"Kim Lorence H.","position":1,"cik":"0001643746","reported_name":"Kim Lorence H.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-09-10T21:52:37.000Z","date":"2026-09-08","kind":"sale","planned":true,"acquired":false,"shares":3844,"price":211.3588,"value":812463.2272,"ownership":{"direct":false,"nature":"Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Lorence Kim Revocable Trust on June 1, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The transaction was executed in multiple trades at prices ranging from $211.00 to $211.9425, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Shares held by the Lorence Kim Revocable Trust."}],"balance_after":371,"source":{"system":"sec-edgar","filing":"0001193125-26-388156","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1643746/000119312526388156/ownership.xml","form_type":"4"}},{"id":4615079,"issuer":{"id":606,"kind":"organization","name":"Revolution Medicines, Inc.","symbol":"RVMD"},"owners":[{"id":607,"kind":"person","name":"Kim Lorence H.","position":1,"cik":"0001643746","reported_name":"Kim Lorence H.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-09-10T21:52:37.000Z","date":"2026-09-08","kind":"sale","planned":true,"acquired":false,"shares":4730,"price":210.5028,"value":995678.244,"ownership":{"direct":false,"nature":"Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Lorence Kim Revocable Trust on June 1, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The transaction was executed in multiple trades at prices ranging from $210.0114 to $210.97, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Shares held by the Lorence Kim Revocable Trust."}],"balance_after":4215,"source":{"system":"sec-edgar","filing":"0001193125-26-388156","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1643746/000119312526388156/ownership.xml","form_type":"4"}},{"id":4615078,"issuer":{"id":606,"kind":"organization","name":"Revolution Medicines, Inc.","symbol":"RVMD"},"owners":[{"id":607,"kind":"person","name":"Kim Lorence H.","position":1,"cik":"0001643746","reported_name":"Kim Lorence H.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-09-10T21:52:37.000Z","date":"2026-09-08","kind":"sale","planned":true,"acquired":false,"shares":2853,"price":209.56,"value":597874.68,"ownership":{"direct":false,"nature":"Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Lorence Kim Revocable Trust on June 1, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The transaction was executed in multiple trades at prices ranging from $209.08 to $209.9809, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Shares held by the Lorence Kim Revocable Trust."}],"balance_after":8945,"source":{"system":"sec-edgar","filing":"0001193125-26-388156","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1643746/000119312526388156/ownership.xml","form_type":"4"}},{"id":4615077,"issuer":{"id":606,"kind":"organization","name":"Revolution Medicines, Inc.","symbol":"RVMD"},"owners":[{"id":607,"kind":"person","name":"Kim Lorence H.","position":1,"cik":"0001643746","reported_name":"Kim Lorence H.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-09-10T21:52:37.000Z","date":"2026-09-08","kind":"sale","planned":true,"acquired":false,"shares":3587,"price":208.5534,"value":748081.0458,"ownership":{"direct":false,"nature":"Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Lorence Kim Revocable Trust on June 1, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The transaction was executed in multiple trades at prices ranging from $208.05 to $208.96, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Shares held by the Lorence Kim Revocable Trust."}],"balance_after":11798,"source":{"system":"sec-edgar","filing":"0001193125-26-388156","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1643746/000119312526388156/ownership.xml","form_type":"4"}},{"id":4615076,"issuer":{"id":606,"kind":"organization","name":"Revolution Medicines, Inc.","symbol":"RVMD"},"owners":[{"id":607,"kind":"person","name":"Kim Lorence H.","position":1,"cik":"0001643746","reported_name":"Kim Lorence H.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-09-10T21:52:37.000Z","date":"2026-09-08","kind":"sale","planned":true,"acquired":false,"shares":999,"price":207.3321,"value":207124.7679,"ownership":{"direct":false,"nature":"Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Lorence Kim Revocable Trust on June 1, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The transaction was executed in multiple trades at prices ranging from $207.02 to $207.70, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Shares held by the Lorence Kim Revocable Trust."}],"balance_after":15385,"source":{"system":"sec-edgar","filing":"0001193125-26-388156","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1643746/000119312526388156/ownership.xml","form_type":"4"}},{"id":4615075,"issuer":{"id":606,"kind":"organization","name":"Revolution Medicines, Inc.","symbol":"RVMD"},"owners":[{"id":607,"kind":"person","name":"Kim Lorence H.","position":1,"cik":"0001643746","reported_name":"Kim Lorence H.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-09-10T21:52:37.000Z","date":"2026-09-08","kind":"sale","planned":true,"acquired":false,"shares":706,"price":206.6049,"value":145863.0594,"ownership":{"direct":false,"nature":"Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Lorence Kim Revocable Trust on June 1, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transaction was executed in multiple trades at prices ranging from $206.47 to $206.9903, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Shares held by the Lorence Kim Revocable Trust."}],"balance_after":16384,"source":{"system":"sec-edgar","filing":"0001193125-26-388156","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1643746/000119312526388156/ownership.xml","form_type":"4"}},{"id":681,"issuer":{"id":606,"kind":"organization","name":"Revolution Medicines, Inc.","symbol":"RVMD"},"owners":[{"id":607,"kind":"person","name":"Kim Lorence H.","position":1,"cik":"0001643746","reported_name":"Kim Lorence H.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-09-02T20:30:26.000Z","date":"2026-08-31","kind":"sale","planned":true,"acquired":false,"shares":625,"price":206.154,"value":128846.25,"ownership":{"direct":false,"nature":"Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Lorence Kim Revocable Trust on June 1, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The transaction was executed in multiple trades at prices ranging from $206.02 to $206.29, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares held by the Lorence Kim Revocable Trust  (the \"Trust\").  Of the 73,090 shares held by the Trust immediately prior to the transactions reported herein, 50,000 shares were acquired by the Trust in July 2022 and were previously reported as directly owned by the Reporting Person, and 23,090 shares were transferred by the Reporting Person to the Trust in August 2025. The August 2025 transfer effected only a change in the form of beneficial ownership without a change in the Reporting Person's pecuniary interest and was exempt pursuant to Rule 16a-13."}],"balance_after":17090,"source":{"system":"sec-edgar","filing":"0001193125-26-380277","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1643746/000119312526380277/ownership.xml","form_type":"4"}},{"id":680,"issuer":{"id":606,"kind":"organization","name":"Revolution Medicines, Inc.","symbol":"RVMD"},"owners":[{"id":607,"kind":"person","name":"Kim Lorence H.","position":1,"cik":"0001643746","reported_name":"Kim Lorence H.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-09-02T20:30:26.000Z","date":"2026-08-31","kind":"sale","planned":true,"acquired":false,"shares":2128,"price":205.1879,"value":436639.8512,"ownership":{"direct":false,"nature":"Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Lorence Kim Revocable Trust on June 1, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The transaction was executed in multiple trades at prices ranging from $205.00 to $205.93, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares held by the Lorence Kim Revocable Trust  (the \"Trust\").  Of the 73,090 shares held by the Trust immediately prior to the transactions reported herein, 50,000 shares were acquired by the Trust in July 2022 and were previously reported as directly owned by the Reporting Person, and 23,090 shares were transferred by the Reporting Person to the Trust in August 2025. The August 2025 transfer effected only a change in the form of beneficial ownership without a change in the Reporting Person's pecuniary interest and was exempt pursuant to Rule 16a-13."}],"balance_after":17715,"source":{"system":"sec-edgar","filing":"0001193125-26-380277","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1643746/000119312526380277/ownership.xml","form_type":"4"}},{"id":679,"issuer":{"id":606,"kind":"organization","name":"Revolution Medicines, Inc.","symbol":"RVMD"},"owners":[{"id":607,"kind":"person","name":"Kim Lorence H.","position":1,"cik":"0001643746","reported_name":"Kim Lorence H.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-09-02T20:30:26.000Z","date":"2026-08-31","kind":"sale","planned":true,"acquired":false,"shares":7271,"price":204.3501,"value":1485829.5771,"ownership":{"direct":false,"nature":"Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Lorence Kim Revocable Trust on June 1, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The transaction was executed in multiple trades at prices ranging from $204.00 to $204.99, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares held by the Lorence Kim Revocable Trust  (the \"Trust\").  Of the 73,090 shares held by the Trust immediately prior to the transactions reported herein, 50,000 shares were acquired by the Trust in July 2022 and were previously reported as directly owned by the Reporting Person, and 23,090 shares were transferred by the Reporting Person to the Trust in August 2025. The August 2025 transfer effected only a change in the form of beneficial ownership without a change in the Reporting Person's pecuniary interest and was exempt pursuant to Rule 16a-13."}],"balance_after":19843,"source":{"system":"sec-edgar","filing":"0001193125-26-380277","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1643746/000119312526380277/ownership.xml","form_type":"4"}},{"id":678,"issuer":{"id":606,"kind":"organization","name":"Revolution Medicines, Inc.","symbol":"RVMD"},"owners":[{"id":607,"kind":"person","name":"Kim Lorence H.","position":1,"cik":"0001643746","reported_name":"Kim Lorence H.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-09-02T20:30:26.000Z","date":"2026-08-31","kind":"sale","planned":true,"acquired":false,"shares":26160,"price":203.5483,"value":5324823.528,"ownership":{"direct":false,"nature":"Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Lorence Kim Revocable Trust on June 1, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The transaction was executed in multiple trades at prices ranging from $203.0055 to $203.9968, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares held by the Lorence Kim Revocable Trust  (the \"Trust\").  Of the 73,090 shares held by the Trust immediately prior to the transactions reported herein, 50,000 shares were acquired by the Trust in July 2022 and were previously reported as directly owned by the Reporting Person, and 23,090 shares were transferred by the Reporting Person to the Trust in August 2025. The August 2025 transfer effected only a change in the form of beneficial ownership without a change in the Reporting Person's pecuniary interest and was exempt pursuant to Rule 16a-13."}],"balance_after":27114,"source":{"system":"sec-edgar","filing":"0001193125-26-380277","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1643746/000119312526380277/ownership.xml","form_type":"4"}},{"id":677,"issuer":{"id":606,"kind":"organization","name":"Revolution Medicines, Inc.","symbol":"RVMD"},"owners":[{"id":607,"kind":"person","name":"Kim Lorence H.","position":1,"cik":"0001643746","reported_name":"Kim Lorence H.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-09-02T20:30:26.000Z","date":"2026-08-31","kind":"sale","planned":true,"acquired":false,"shares":12919,"price":202.4819,"value":2615863.6661,"ownership":{"direct":false,"nature":"Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Lorence Kim Revocable Trust on June 1, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The transaction was executed in multiple trades at prices ranging from $202.00 to $202.9956, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares held by the Lorence Kim Revocable Trust  (the \"Trust\").  Of the 73,090 shares held by the Trust immediately prior to the transactions reported herein, 50,000 shares were acquired by the Trust in July 2022 and were previously reported as directly owned by the Reporting Person, and 23,090 shares were transferred by the Reporting Person to the Trust in August 2025. The August 2025 transfer effected only a change in the form of beneficial ownership without a change in the Reporting Person's pecuniary interest and was exempt pursuant to Rule 16a-13."}],"balance_after":53274,"source":{"system":"sec-edgar","filing":"0001193125-26-380277","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1643746/000119312526380277/ownership.xml","form_type":"4"}},{"id":676,"issuer":{"id":606,"kind":"organization","name":"Revolution Medicines, Inc.","symbol":"RVMD"},"owners":[{"id":607,"kind":"person","name":"Kim Lorence H.","position":1,"cik":"0001643746","reported_name":"Kim Lorence H.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-09-02T20:30:26.000Z","date":"2026-08-31","kind":"sale","planned":true,"acquired":false,"shares":6597,"price":201.4729,"value":1329116.7213,"ownership":{"direct":false,"nature":"Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Lorence Kim Revocable Trust on June 1, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transaction was executed in multiple trades at prices ranging from $201.00 to $201.99, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares held by the Lorence Kim Revocable Trust  (the \"Trust\").  Of the 73,090 shares held by the Trust immediately prior to the transactions reported herein, 50,000 shares were acquired by the Trust in July 2022 and were previously reported as directly owned by the Reporting Person, and 23,090 shares were transferred by the Reporting Person to the Trust in August 2025. The August 2025 transfer effected only a change in the form of beneficial ownership without a change in the Reporting Person's pecuniary interest and was exempt pursuant to Rule 16a-13."}],"balance_after":66193,"source":{"system":"sec-edgar","filing":"0001193125-26-380277","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1643746/000119312526380277/ownership.xml","form_type":"4"}},{"id":675,"issuer":{"id":606,"kind":"organization","name":"Revolution Medicines, Inc.","symbol":"RVMD"},"owners":[{"id":607,"kind":"person","name":"Kim Lorence H.","position":1,"cik":"0001643746","reported_name":"Kim Lorence H.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-09-02T20:30:26.000Z","date":"2026-08-31","kind":"sale","planned":true,"acquired":false,"shares":300,"price":200.56,"value":60168.0,"ownership":{"direct":false,"nature":"Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Lorence Kim Revocable Trust on June 1, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares held by the Lorence Kim Revocable Trust  (the \"Trust\").  Of the 73,090 shares held by the Trust immediately prior to the transactions reported herein, 50,000 shares were acquired by the Trust in July 2022 and were previously reported as directly owned by the Reporting Person, and 23,090 shares were transferred by the Reporting Person to the Trust in August 2025. The August 2025 transfer effected only a change in the form of beneficial ownership without a change in the Reporting Person's pecuniary interest and was exempt pursuant to Rule 16a-13."}],"balance_after":72790,"source":{"system":"sec-edgar","filing":"0001193125-26-380277","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1643746/000119312526380277/ownership.xml","form_type":"4"}},{"id":675805,"issuer":{"id":606,"kind":"organization","name":"Revolution Medicines, Inc.","symbol":"RVMD"},"owners":[{"id":19800,"kind":"person","name":"Cislini Jeff","position":1,"cik":"0001969082","reported_name":"Cislini Jeff","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-08-25T20:06:49.000Z","date":"2026-08-21","kind":"exercise","planned":true,"acquired":false,"shares":26600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on May 22, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"One forty-eighth (1/48th) of the shares initially subject to the option will vest on each monthly anniversary measured from September 1, 2022 (the \"Vesting Commencement Date\"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date."}],"balance_after":3500,"derivative":{"exercise_price":21.61,"expiration_date":"2032-08-31","underlying":"Common Stock","underlying_shares":26600},"source":{"system":"sec-edgar","filing":"0001610717-26-000388","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1628171/000161071726000388/form4.xml","form_type":"4"}},{"id":675804,"issuer":{"id":606,"kind":"organization","name":"Revolution Medicines, Inc.","symbol":"RVMD"},"owners":[{"id":19800,"kind":"person","name":"Cislini Jeff","position":1,"cik":"0001969082","reported_name":"Cislini Jeff","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-08-25T20:06:49.000Z","date":"2026-08-21","kind":"exercise","planned":true,"acquired":false,"shares":29680,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on May 22, 2026."}],"balance_after":0,"derivative":{"exercise_price":18.56,"exercise_date":"2026-03-01","expiration_date":"2032-02-29","underlying":"Common Stock","underlying_shares":29680},"source":{"system":"sec-edgar","filing":"0001610717-26-000388","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1628171/000161071726000388/form4.xml","form_type":"4"}},{"id":675803,"issuer":{"id":606,"kind":"organization","name":"Revolution Medicines, Inc.","symbol":"RVMD"},"owners":[{"id":19800,"kind":"person","name":"Cislini Jeff","position":1,"cik":"0001969082","reported_name":"Cislini Jeff","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2026-08-25T20:06:49.000Z","date":"2026-08-21","kind":"sale","planned":true,"acquired":false,"shares":3314,"price":212.0583,"value":702761.2062,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on May 22, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"This transaction was executed in multiple trades in prices ranging from $211.77 to $212.74, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 43,514 restricted stock units."}],"balance_after":55907,"source":{"system":"sec-edgar","filing":"0001610717-26-000388","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1628171/000161071726000388/form4.xml","form_type":"4"}},{"id":675802,"issuer":{"id":606,"kind":"organization","name":"Revolution Medicines, Inc.","symbol":"RVMD"},"owners":[{"id":19800,"kind":"person","name":"Cislini Jeff","position":1,"cik":"0001969082","reported_name":"Cislini Jeff","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2026-08-25T20:06:49.000Z","date":"2026-08-21","kind":"sale","planned":true,"acquired":false,"shares":4500,"price":211.3417,"value":951037.65,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on May 22, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"This transaction was executed in multiple trades in prices ranging from $210.77 to $211.76, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 43,514 restricted stock units."}],"balance_after":59221,"source":{"system":"sec-edgar","filing":"0001610717-26-000388","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1628171/000161071726000388/form4.xml","form_type":"4"}},{"id":675801,"issuer":{"id":606,"kind":"organization","name":"Revolution Medicines, Inc.","symbol":"RVMD"},"owners":[{"id":19800,"kind":"person","name":"Cislini Jeff","position":1,"cik":"0001969082","reported_name":"Cislini Jeff","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2026-08-25T20:06:49.000Z","date":"2026-08-21","kind":"sale","planned":true,"acquired":false,"shares":2540,"price":210.2647,"value":534072.338,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on May 22, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"This transaction was executed in multiple trades in prices ranging from $209.77 to $210.72, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 43,514 restricted stock units."}],"balance_after":63721,"source":{"system":"sec-edgar","filing":"0001610717-26-000388","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1628171/000161071726000388/form4.xml","form_type":"4"}},{"id":675800,"issuer":{"id":606,"kind":"organization","name":"Revolution Medicines, Inc.","symbol":"RVMD"},"owners":[{"id":19800,"kind":"person","name":"Cislini Jeff","position":1,"cik":"0001969082","reported_name":"Cislini Jeff","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2026-08-25T20:06:49.000Z","date":"2026-08-21","kind":"sale","planned":true,"acquired":false,"shares":25817,"price":209.2497,"value":5402199.5049,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on May 22, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"This transaction was executed in multiple trades in prices ranging from $208.77 to $209.61, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 43,514 restricted stock units."}],"balance_after":66261,"source":{"system":"sec-edgar","filing":"0001610717-26-000388","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1628171/000161071726000388/form4.xml","form_type":"4"}},{"id":675799,"issuer":{"id":606,"kind":"organization","name":"Revolution Medicines, Inc.","symbol":"RVMD"},"owners":[{"id":19800,"kind":"person","name":"Cislini Jeff","position":1,"cik":"0001969082","reported_name":"Cislini Jeff","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2026-08-25T20:06:49.000Z","date":"2026-08-21","kind":"sale","planned":true,"acquired":false,"shares":17323,"price":208.3688,"value":3609572.7224,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on May 22, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"This transaction was executed in multiple trades in prices ranging from $207.765 to $208.75, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."}],"balance_after":92078,"source":{"system":"sec-edgar","filing":"0001610717-26-000388","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1628171/000161071726000388/form4.xml","form_type":"4"}},{"id":675798,"issuer":{"id":606,"kind":"organization","name":"Revolution Medicines, Inc.","symbol":"RVMD"},"owners":[{"id":19800,"kind":"person","name":"Cislini Jeff","position":1,"cik":"0001969082","reported_name":"Cislini Jeff","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2026-08-25T20:06:49.000Z","date":"2026-08-21","kind":"sale","planned":true,"acquired":false,"shares":3400,"price":207.2363,"value":704603.42,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on May 22, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This transaction was executed in multiple trades in prices ranging from $206.76 to $207.75, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 43,514 restricted stock units."}],"balance_after":109401,"source":{"system":"sec-edgar","filing":"0001610717-26-000388","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1628171/000161071726000388/form4.xml","form_type":"4"}},{"id":675797,"issuer":{"id":606,"kind":"organization","name":"Revolution Medicines, Inc.","symbol":"RVMD"},"owners":[{"id":19800,"kind":"person","name":"Cislini Jeff","position":1,"cik":"0001969082","reported_name":"Cislini Jeff","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2026-08-25T20:06:49.000Z","date":"2026-08-21","kind":"exercise","planned":true,"acquired":true,"shares":26600,"price":21.61,"value":574826.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on May 22, 2026."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 43,514 restricted stock units."}],"balance_after":112801,"source":{"system":"sec-edgar","filing":"0001610717-26-000388","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1628171/000161071726000388/form4.xml","form_type":"4"}},{"id":675796,"issuer":{"id":606,"kind":"organization","name":"Revolution Medicines, Inc.","symbol":"RVMD"},"owners":[{"id":19800,"kind":"person","name":"Cislini Jeff","position":1,"cik":"0001969082","reported_name":"Cislini Jeff","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2026-08-25T20:06:49.000Z","date":"2026-08-21","kind":"exercise","planned":true,"acquired":true,"shares":29680,"price":18.56,"value":550860.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on May 22, 2026."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 43,514 restricted stock units."}],"balance_after":86201,"source":{"system":"sec-edgar","filing":"0001610717-26-000388","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1628171/000161071726000388/form4.xml","form_type":"4"}},{"id":675994,"issuer":{"id":606,"kind":"organization","name":"Revolution Medicines, Inc.","symbol":"RVMD"},"owners":[{"id":19850,"kind":"person","name":"GOLDSMITH MARK A","position":1,"cik":"0001246842","reported_name":"GOLDSMITH MARK A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-08-25T20:06:12.000Z","date":"2026-08-21","kind":"exercise","planned":true,"acquired":false,"shares":80000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by Mark A. Goldsmith on May 22, 2026."}],"balance_after":344085,"derivative":{"exercise_price":4.73,"exercise_date":"2023-08-09","expiration_date":"2029-08-08","underlying":"Common Stock","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0001610717-26-000387","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":21,"url":"https://www.sec.gov/Archives/edgar/data/1246842/000161071726000387/form4.xml","form_type":"4"}},{"id":675993,"issuer":{"id":606,"kind":"organization","name":"Revolution Medicines, Inc.","symbol":"RVMD"},"owners":[{"id":19850,"kind":"person","name":"GOLDSMITH MARK A","position":1,"cik":"0001246842","reported_name":"GOLDSMITH MARK A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-08-25T20:06:12.000Z","date":"2026-08-21","kind":"sale","planned":true,"acquired":false,"shares":126,"price":212.0641,"value":26720.0766,"ownership":{"direct":false,"nature":"Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F15","text":"This transaction was executed in multiple trades at prices ranging from $212.00 to $212.13. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F16","text":"Held by Rebecca Goldsmith Revocable Trust."}],"balance_after":61424,"source":{"system":"sec-edgar","filing":"0001610717-26-000387","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":19,"url":"https://www.sec.gov/Archives/edgar/data/1246842/000161071726000387/form4.xml","form_type":"4"}},{"id":675992,"issuer":{"id":606,"kind":"organization","name":"Revolution Medicines, Inc.","symbol":"RVMD"},"owners":[{"id":19850,"kind":"person","name":"GOLDSMITH MARK A","position":1,"cik":"0001246842","reported_name":"GOLDSMITH MARK A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-08-25T20:06:12.000Z","date":"2026-08-21","kind":"sale","planned":true,"acquired":false,"shares":229,"price":211.4648,"value":48425.4392,"ownership":{"direct":false,"nature":"Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F14","text":"This transaction was executed in multiple trades at prices ranging from $210.93 to $211.85. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F16","text":"Held by Rebecca Goldsmith Revocable Trust."}],"balance_after":61550,"source":{"system":"sec-edgar","filing":"0001610717-26-000387","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/1246842/000161071726000387/form4.xml","form_type":"4"}},{"id":675991,"issuer":{"id":606,"kind":"organization","name":"Revolution Medicines, Inc.","symbol":"RVMD"},"owners":[{"id":19850,"kind":"person","name":"GOLDSMITH MARK A","position":1,"cik":"0001246842","reported_name":"GOLDSMITH MARK A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-08-25T20:06:12.000Z","date":"2026-08-21","kind":"sale","planned":true,"acquired":false,"shares":126,"price":210.403,"value":26510.778,"ownership":{"direct":false,"nature":"Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F13","text":"This transaction was executed in multiple trades at prices ranging from $209.87 to $210.81. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F16","text":"Held by Rebecca Goldsmith Revocable Trust."}],"balance_after":61779,"source":{"system":"sec-edgar","filing":"0001610717-26-000387","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1246842/000161071726000387/form4.xml","form_type":"4"}},{"id":675990,"issuer":{"id":606,"kind":"organization","name":"Revolution Medicines, Inc.","symbol":"RVMD"},"owners":[{"id":19850,"kind":"person","name":"GOLDSMITH MARK A","position":1,"cik":"0001246842","reported_name":"GOLDSMITH MARK A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-08-25T20:06:12.000Z","date":"2026-08-21","kind":"sale","planned":true,"acquired":false,"shares":1405,"price":209.2664,"value":294019.292,"ownership":{"direct":false,"nature":"Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F18","text":"This transaction was executed in multiple trades at prices ranging from $208.80 to $209.63. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F16","text":"Held by Rebecca Goldsmith Revocable Trust."}],"balance_after":61905,"source":{"system":"sec-edgar","filing":"0001610717-26-000387","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1246842/000161071726000387/form4.xml","form_type":"4"}},{"id":675989,"issuer":{"id":606,"kind":"organization","name":"Revolution Medicines, Inc.","symbol":"RVMD"},"owners":[{"id":19850,"kind":"person","name":"GOLDSMITH MARK A","position":1,"cik":"0001246842","reported_name":"GOLDSMITH MARK A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-08-25T20:06:12.000Z","date":"2026-08-21","kind":"sale","planned":true,"acquired":false,"shares":937,"price":208.3609,"value":195234.1633,"ownership":{"direct":false,"nature":"Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F17","text":"This transaction was executed in multiple trades at prices ranging from $207.80 to $208.77. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F16","text":"Held by Rebecca Goldsmith Revocable Trust."}],"balance_after":63310,"source":{"system":"sec-edgar","filing":"0001610717-26-000387","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1246842/000161071726000387/form4.xml","form_type":"4"}},{"id":675988,"issuer":{"id":606,"kind":"organization","name":"Revolution Medicines, Inc.","symbol":"RVMD"},"owners":[{"id":19850,"kind":"person","name":"GOLDSMITH MARK A","position":1,"cik":"0001246842","reported_name":"GOLDSMITH MARK A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-08-25T20:06:12.000Z","date":"2026-08-21","kind":"sale","planned":true,"acquired":false,"shares":177,"price":207.2515,"value":36683.5155,"ownership":{"direct":false,"nature":"Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F9","text":"This transaction was executed in multiple trades at prices ranging from $206.78 to $207.73. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F16","text":"Held by Rebecca Goldsmith Revocable Trust."}],"balance_after":64247,"source":{"system":"sec-edgar","filing":"0001610717-26-000387","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1246842/000161071726000387/form4.xml","form_type":"4"}},{"id":675987,"issuer":{"id":606,"kind":"organization","name":"Revolution Medicines, Inc.","symbol":"RVMD"},"owners":[{"id":19850,"kind":"person","name":"GOLDSMITH MARK A","position":1,"cik":"0001246842","reported_name":"GOLDSMITH MARK A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-08-25T20:06:12.000Z","date":"2026-08-21","kind":"sale","planned":true,"acquired":false,"shares":127,"price":212.0635,"value":26932.0645,"ownership":{"direct":false,"nature":"Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F15","text":"This transaction was executed in multiple trades at prices ranging from $212.00 to $212.13. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"Held by Jonathan Goldsmith Revocable Trust."}],"balance_after":61424,"source":{"system":"sec-edgar","filing":"0001610717-26-000387","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1246842/000161071726000387/form4.xml","form_type":"4"}},{"id":675986,"issuer":{"id":606,"kind":"organization","name":"Revolution Medicines, Inc.","symbol":"RVMD"},"owners":[{"id":19850,"kind":"person","name":"GOLDSMITH MARK A","position":1,"cik":"0001246842","reported_name":"GOLDSMITH MARK A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-08-25T20:06:12.000Z","date":"2026-08-21","kind":"sale","planned":true,"acquired":false,"shares":245,"price":211.4651,"value":51808.9495,"ownership":{"direct":false,"nature":"Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F14","text":"This transaction was executed in multiple trades at prices ranging from $210.93 to $211.85. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"Held by Jonathan Goldsmith Revocable Trust."}],"balance_after":61551,"source":{"system":"sec-edgar","filing":"0001610717-26-000387","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1246842/000161071726000387/form4.xml","form_type":"4"}},{"id":675985,"issuer":{"id":606,"kind":"organization","name":"Revolution Medicines, Inc.","symbol":"RVMD"},"owners":[{"id":19850,"kind":"person","name":"GOLDSMITH MARK A","position":1,"cik":"0001246842","reported_name":"GOLDSMITH MARK A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-08-25T20:06:12.000Z","date":"2026-08-21","kind":"sale","planned":true,"acquired":false,"shares":136,"price":210.4017,"value":28614.6312,"ownership":{"direct":false,"nature":"Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F13","text":"This transaction was executed in multiple trades at prices ranging from $209.87 to $210.81. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"Held by Jonathan Goldsmith Revocable Trust."}],"balance_after":61796,"source":{"system":"sec-edgar","filing":"0001610717-26-000387","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1246842/000161071726000387/form4.xml","form_type":"4"}},{"id":675984,"issuer":{"id":606,"kind":"organization","name":"Revolution Medicines, Inc.","symbol":"RVMD"},"owners":[{"id":19850,"kind":"person","name":"GOLDSMITH MARK A","position":1,"cik":"0001246842","reported_name":"GOLDSMITH MARK A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-08-25T20:06:12.000Z","date":"2026-08-21","kind":"sale","planned":true,"acquired":false,"shares":1351,"price":209.2812,"value":282738.9012,"ownership":{"direct":false,"nature":"Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F12","text":"This transaction was executed in multiple trades at prices ranging from $208.84 to $209.60. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"Held by Jonathan Goldsmith Revocable Trust."}],"balance_after":61932,"source":{"system":"sec-edgar","filing":"0001610717-26-000387","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1246842/000161071726000387/form4.xml","form_type":"4"}},{"id":675983,"issuer":{"id":606,"kind":"organization","name":"Revolution Medicines, Inc.","symbol":"RVMD"},"owners":[{"id":19850,"kind":"person","name":"GOLDSMITH MARK A","position":1,"cik":"0001246842","reported_name":"GOLDSMITH MARK A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-08-25T20:06:12.000Z","date":"2026-08-21","kind":"sale","planned":true,"acquired":false,"shares":951,"price":208.3648,"value":198154.9248,"ownership":{"direct":false,"nature":"Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F11","text":"This transaction was executed in multiple trades at prices ranging from $207.84 to $208.82. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"Held by Jonathan Goldsmith Revocable Trust."}],"balance_after":63283,"source":{"system":"sec-edgar","filing":"0001610717-26-000387","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1246842/000161071726000387/form4.xml","form_type":"4"}},{"id":675982,"issuer":{"id":606,"kind":"organization","name":"Revolution Medicines, Inc.","symbol":"RVMD"},"owners":[{"id":19850,"kind":"person","name":"GOLDSMITH MARK A","position":1,"cik":"0001246842","reported_name":"GOLDSMITH MARK A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-08-25T20:06:12.000Z","date":"2026-08-21","kind":"sale","planned":true,"acquired":false,"shares":190,"price":207.2454,"value":39376.626,"ownership":{"direct":false,"nature":"Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F9","text":"This transaction was executed in multiple trades at prices ranging from $206.78 to $207.73. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"Held by Jonathan Goldsmith Revocable Trust."}],"balance_after":64234,"source":{"system":"sec-edgar","filing":"0001610717-26-000387","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1246842/000161071726000387/form4.xml","form_type":"4"}},{"id":675981,"issuer":{"id":606,"kind":"organization","name":"Revolution Medicines, Inc.","symbol":"RVMD"},"owners":[{"id":19850,"kind":"person","name":"GOLDSMITH MARK A","position":1,"cik":"0001246842","reported_name":"GOLDSMITH MARK A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-08-25T20:06:12.000Z","date":"2026-08-21","kind":"sale","planned":true,"acquired":false,"shares":3621,"price":212.0776,"value":767932.9896,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by Mark A. Goldsmith on May 22, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"This transaction was executed in multiple trades at prices ranging from $211.82 to $212.74. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 182,938 restricted stock units."}],"balance_after":267330,"source":{"system":"sec-edgar","filing":"0001610717-26-000387","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1246842/000161071726000387/form4.xml","form_type":"4"}},{"id":675980,"issuer":{"id":606,"kind":"organization","name":"Revolution Medicines, Inc.","symbol":"RVMD"},"owners":[{"id":19850,"kind":"person","name":"GOLDSMITH MARK A","position":1,"cik":"0001246842","reported_name":"GOLDSMITH MARK A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-08-25T20:06:12.000Z","date":"2026-08-21","kind":"sale","planned":true,"acquired":false,"shares":6583,"price":211.3331,"value":1391205.7973,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by Mark A. Goldsmith on May 22, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"This transaction was executed in multiple trades at prices ranging from $210.81 to $211.77. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 182,938 restricted stock units."}],"balance_after":270951,"source":{"system":"sec-edgar","filing":"0001610717-26-000387","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1246842/000161071726000387/form4.xml","form_type":"4"}},{"id":675979,"issuer":{"id":606,"kind":"organization","name":"Revolution Medicines, Inc.","symbol":"RVMD"},"owners":[{"id":19850,"kind":"person","name":"GOLDSMITH MARK A","position":1,"cik":"0001246842","reported_name":"GOLDSMITH MARK A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-08-25T20:06:12.000Z","date":"2026-08-21","kind":"sale","planned":true,"acquired":false,"shares":3813,"price":210.2466,"value":801670.2858,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by Mark A. Goldsmith on May 22, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"This transaction was executed in multiple trades at prices ranging from $209.80 to $210.75. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 182,938 restricted stock units."}],"balance_after":277534,"source":{"system":"sec-edgar","filing":"0001610717-26-000387","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1246842/000161071726000387/form4.xml","form_type":"4"}},{"id":675978,"issuer":{"id":606,"kind":"organization","name":"Revolution Medicines, Inc.","symbol":"RVMD"},"owners":[{"id":19850,"kind":"person","name":"GOLDSMITH MARK A","position":1,"cik":"0001246842","reported_name":"GOLDSMITH MARK A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-08-25T20:06:12.000Z","date":"2026-08-21","kind":"sale","planned":true,"acquired":false,"shares":35938,"price":209.2615,"value":7520439.787,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by Mark A. Goldsmith on May 22, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"This transaction was executed in multiple trades at prices ranging from $208.80 to $209.78. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 182,938 restricted stock units."}],"balance_after":281347,"source":{"system":"sec-edgar","filing":"0001610717-26-000387","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1246842/000161071726000387/form4.xml","form_type":"4"}},{"id":675977,"issuer":{"id":606,"kind":"organization","name":"Revolution Medicines, Inc.","symbol":"RVMD"},"owners":[{"id":19850,"kind":"person","name":"GOLDSMITH MARK A","position":1,"cik":"0001246842","reported_name":"GOLDSMITH MARK A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-08-25T20:06:12.000Z","date":"2026-08-21","kind":"sale","planned":true,"acquired":false,"shares":24917,"price":208.3697,"value":5191947.8149,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by Mark A. Goldsmith on May 22, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"This transaction was executed in multiple trades at prices ranging from $207.79 to $208.78. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 182,938 restricted stock units."}],"balance_after":317285,"source":{"system":"sec-edgar","filing":"0001610717-26-000387","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1246842/000161071726000387/form4.xml","form_type":"4"}},{"id":675976,"issuer":{"id":606,"kind":"organization","name":"Revolution Medicines, Inc.","symbol":"RVMD"},"owners":[{"id":19850,"kind":"person","name":"GOLDSMITH MARK A","position":1,"cik":"0001246842","reported_name":"GOLDSMITH MARK A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-08-25T20:06:12.000Z","date":"2026-08-21","kind":"sale","planned":true,"acquired":false,"shares":5128,"price":207.233,"value":1062690.824,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by Mark A. Goldsmith on May 22, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This transaction was executed in multiple trades at prices ranging from $206.78 to $207.7750. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 182,938 restricted stock units."}],"balance_after":342202,"source":{"system":"sec-edgar","filing":"0001610717-26-000387","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1246842/000161071726000387/form4.xml","form_type":"4"}},{"id":675975,"issuer":{"id":606,"kind":"organization","name":"Revolution Medicines, Inc.","symbol":"RVMD"},"owners":[{"id":19850,"kind":"person","name":"GOLDSMITH MARK A","position":1,"cik":"0001246842","reported_name":"GOLDSMITH MARK A","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-08-25T20:06:12.000Z","date":"2026-08-21","kind":"exercise","planned":true,"acquired":true,"shares":80000,"price":4.73,"value":378400.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by Mark A. Goldsmith on May 22, 2026."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 182,938 restricted stock units."}],"balance_after":347330,"source":{"system":"sec-edgar","filing":"0001610717-26-000387","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1246842/000161071726000387/form4.xml","form_type":"4"}},{"id":721378,"issuer":{"id":606,"kind":"organization","name":"Revolution Medicines, Inc.","symbol":"RVMD"},"owners":[{"id":24169,"kind":"person","name":"Patel Sushil","position":1,"cik":"0001860609","reported_name":"Patel Sushil","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-07-01T22:25:05.000Z","date":"2026-06-29","kind":"exercise","planned":true,"acquired":false,"shares":2955,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by Sushil Patel on March 30, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"Fully vested."}],"balance_after":13000,"derivative":{"exercise_price":37.54,"expiration_date":"2034-06-19","underlying":"Common Stock","underlying_shares":2955},"source":{"system":"sec-edgar","filing":"0001610717-26-000311","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1860609/000161071726000311/form4.xml","form_type":"4"}},{"id":721377,"issuer":{"id":606,"kind":"organization","name":"Revolution Medicines, Inc.","symbol":"RVMD"},"owners":[{"id":24169,"kind":"person","name":"Patel Sushil","position":1,"cik":"0001860609","reported_name":"Patel Sushil","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-07-01T22:25:05.000Z","date":"2026-06-29","kind":"sale","planned":true,"acquired":false,"shares":881,"price":192.6139,"value":169692.8459,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by Sushil Patel on March 30, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The transaction was executed in multiple trades in prices ranging from $192.55 to $192.64, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 1,191 restricted stock units."}],"balance_after":21656,"source":{"system":"sec-edgar","filing":"0001610717-26-000311","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1860609/000161071726000311/form4.xml","form_type":"4"}},{"id":721376,"issuer":{"id":606,"kind":"organization","name":"Revolution Medicines, Inc.","symbol":"RVMD"},"owners":[{"id":24169,"kind":"person","name":"Patel Sushil","position":1,"cik":"0001860609","reported_name":"Patel Sushil","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-07-01T22:25:05.000Z","date":"2026-06-29","kind":"sale","planned":true,"acquired":false,"shares":541,"price":191.8661,"value":103799.5601,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by Sushil Patel on March 30, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The transaction was executed in multiple trades in prices ranging from $191.47 to $192.40, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 1,191 restricted stock units."}],"balance_after":22537,"source":{"system":"sec-edgar","filing":"0001610717-26-000311","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1860609/000161071726000311/form4.xml","form_type":"4"}}],"next_cursor":"2026-07-01T22:25:05.000000Z,721376"}